ABT

ABT Net Receivables

$8.60BQuarterly · USD

Period ending:

ABT FY Net ReceivablesUSD
ABT FY Net Receivables1985-12-31: $563.30M1986-12-31: $624.90M1987-12-31: $728.00M1988-12-31: $781.80M1989-12-31: $892.70M1990-12-31: $1.07B1991-12-31: $1.15B1992-12-31: $1.24B1993-12-31: $1.34B1994-12-31: $1.47B1995-12-31: $1.56B1996-12-31: $1.71B1997-12-31: $1.78B1998-12-31: $1.96B1999-12-31: $2.06B2000-12-31: $2.18B2001-12-31: $2.81B2002-12-31: $2.93B2003-12-31: $3.31B2004-12-31: $3.70B2005-12-31: $3.58B2006-12-31: $4.23B2007-12-31: $4.95B2008-12-31: $5.47B2009-12-31: $6.54B2010-12-31: $7.18B2011-12-31: $7.68B2012-12-31: $7.61B2013-12-31: $3.99B2014-12-31: $3.59B2015-12-31: $3.42B2016-12-31: $3.25B2017-12-31: $5.25B2018-12-31: $5.18B2019-12-31: $5.43B2020-12-31: $6.41B2021-12-31: $6.49B2022-12-31: $6.22B2023-12-31: $6.57B2024-12-31: $6.93B2025-12-31: $7.93B$7.93B$0.00
1985-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

ABT net receivables history

Net amount expected from customer receivables. The available annual fiscal periods series contains 41 observations from Dec 31, 1985 to Dec 31, 2025.

Abbott Laboratories Net Receivables — Annual fiscal periods (USD)
Period endingNet Receivables (USD)
7,929,000,000
6,925,000,000
6,565,000,000
6,218,000,000
6,487,000,000
6,414,000,000
5,425,000,000
5,182,000,000
5,249,000,000
3,248,000,000
3,418,000,000
3,586,000,000
3,986,000,000
7,613,000,000
7,683,920,000
7,184,034,000
6,541,941,000
5,465,660,000
4,946,876,000
4,231,142,000
3,576,794,000
3,696,115,000
3,313,377,000
2,927,370,000
2,812,727,000
2,179,451,000
2,055,839,000
1,955,900,000
1,782,300,000
1,708,800,000
1,563,038,000
1,468,519,000
1,336,222,000
1,244,400,000
1,150,900,000
1,070,200,000
892,700,000
781,800,000
728,000,000
624,900,000
563,300,000

Compare net receivables

All ABT financial metrics · ABT stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.